Condition 1: Diabetes mellitus. Condition 2: Diabetes mellitus. Condition 3: Metabolic disorders. Non-insulin-dependent diabetes mellitus Malnutrition-related diabetes mellitus Disorders of lipoprotein metabolism and other lipidaemias
Conditions
Interventions
Intervention 1: intervention group : extract of prosopis farcta, 500mg capsule,twice a day ,3 months. Intervention 2: Control group: placebo,500mg capsula including toasted flour twice a day,3 months.
Treatment - Drugs
Placebo
intervention group : extract of prosopis farcta, 500mg capsule,twice a day ,3 months
Control group: placebo,500mg capsula including toasted flour twice a day,3 months
Sponsors
Vice Chancellor for research of zahedan university of medical sciences
Vice Chancellor for research of Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diabetic patients, non insulin dependent and under treatment by glyboride and metformin with maximum dose of 10 and 100 mg. Age between 40 and 60 years at least 2 years diabetic ,mean blood sugar 150 up to180mg/dl in the presence of glucose and lipid reducing drugs; Hb A1c between 5.7 up to 8.5 % in the presence of glucose and lipid reducing drugs without changing dose in 2 months ago. Exclusion criteria: Patients under 40 and above 60 years old ; patients with diabetic foot ulcers and tissue death resulting from hypoperfusion and any Severe illness associated with ( including renal failure, chronic hepatic failure, Uncompensated cardiac failure, Diabetes induced pulmunary infection); active cancer; History of cancer less than 5 years; Depression; smoker and alcoholic Patients; Pregnancy and breastfeeding and women in reproductive time without a reliable method of preventing pregnancy; The desire to change identified sport or diet program; Patients consuming blood sugar and lipid lowering herbal drugs
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood sugar. Timepoint: befor and 3 months after intervention. Method of measurement: Biochemidtry analyzer,mg/dl.;HbA1c. Timepoint: At the begining and 3 months after intervention. Method of measurement: Is measured by chromatographia and presented as percentage. | — |
Secondary
| Measure | Time frame |
|---|---|
| HDL. Timepoint: at the start and 3 months after intervention. Method of measurement: biochemistry analyzer,mg/dl.;LDL. Timepoint: at the start and 3 months after intervention. Method of measurement: biochemistry analyzer,mg/dl.;Triglyceride. Timepoint: at the start and 3 months after intervention. Method of measurement: biochemistry analyzer,mg/dl.;Cholestrol. Timepoint: at the start and 3 months after intervention. Method of measurement: biochemistry analyzer,mg/dl. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactsaeed mehrzadi
IUMS
Outcome results
None listed